• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Concentration- or effect-controlled clinical trials with sparse data.

作者信息

Levy G, Ebling W F, Forrest A

机构信息

Department of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo, Amherst 14260.

出版信息

Clin Pharmacol Ther. 1994 Jul;56(1):1-8. doi: 10.1038/clpt.1994.93.

DOI:10.1038/clpt.1994.93
PMID:8033486
Abstract
摘要

相似文献

1
Concentration- or effect-controlled clinical trials with sparse data.
Clin Pharmacol Ther. 1994 Jul;56(1):1-8. doi: 10.1038/clpt.1994.93.
2
Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations.以一项先导研究为指导的浓度和效应控制临床试验稀疏数据的药效学分析。模拟研究。
J Pharm Sci. 1996 Jun;85(6):600-7. doi: 10.1021/js9504705.
3
Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview.药理学与临床药理学中定量方法的引入：历史概述
Clin Pharmacol Ther. 2007 Jul;82(1):3-6. doi: 10.1038/sj.clpt.6100248.
4
Population pharmacodynamics: strategies for concentration-and effect-controlled clinical trials.群体药效学：浓度和效应控制临床试验策略
Ann Pharmacother. 1996 Jan;30(1):12-9. doi: 10.1177/106002809603000102.
5
Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling.基于药代动力学/药效学模型，通过计算机模拟探索临床研究设计。
Int J Clin Pharmacol Ther. 1997 Oct;35(10):469-74.
6
[Using CTS and PK-PD models to predict the effect of uncertainty about population parameters on clinical trial power].[使用CTS和PK-PD模型预测总体参数不确定性对临床试验效能的影响]
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2009 Feb;26(1):42-6, 62.
7
Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials?浓度控制或效应控制试验：传统剂量控制试验的有用替代方法？
Clin Pharmacokinet. 2001;40(5):317-25. doi: 10.2165/00003088-200140050-00001.
8
Clinical trial simulation of a 200-microg fixed dose of darbepoetin alfa in chemotherapy-induced anemia.
Oncology (Williston Park). 2002 Oct;16(10 Suppl 11):37-44.
9
Clinical trial optimization: Monte Carlo simulation Markov model for planning clinical trials recruitment.临床试验优化：用于规划临床试验招募的蒙特卡洛模拟马尔可夫模型
Contemp Clin Trials. 2007 May;28(3):220-31. doi: 10.1016/j.cct.2006.08.002. Epub 2006 Aug 10.
10
Design of clinical pharmacology trials.临床药理学试验设计
Clin Exp Pharmacol Physiol. 2001 Nov;28(11):905-12. doi: 10.1046/j.1440-1681.2001.03546.x.

引用本文的文献

1
DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model.DS-1205b是一种新型AXL激酶选择性抑制剂，在非小细胞肺癌异种移植模型中可阻断对表皮生长因子受体酪氨酸激酶抑制剂的耐药性。
Oncotarget. 2019 Aug 27;10(50):5152-5167. doi: 10.18632/oncotarget.27114.
2
Integrated pharmacokinetics and pharmacodynamics in drug development.药物研发中的整合药代动力学与药效学
Clin Pharmacokinet. 2007;46(9):713-37. doi: 10.2165/00003088-200746090-00001.
3
Drug-gene interactions between genetic polymorphisms and antihypertensive therapy.
基因多态性与抗高血压治疗之间的药物-基因相互作用。
Drugs. 2004;64(16):1801-16. doi: 10.2165/00003495-200464160-00006.
4
Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials?浓度控制或效应控制试验：传统剂量控制试验的有用替代方法？
Clin Pharmacokinet. 2001;40(5):317-25. doi: 10.2165/00003088-200140050-00001.
5
Biomarkers of environmental tobacco smoke exposure.环境烟草烟雾暴露的生物标志物。
Environ Health Perspect. 1999 May;107 Suppl 2(Suppl 2):349-55. doi: 10.1289/ehp.99107s2349.
6
Midazolam effects on prepulse inhibition of the acoustic blink reflex.咪达唑仑对听觉眨眼反射的前脉冲抑制作用。
Br J Clin Pharmacol. 1999 Apr;47(4):421-6. doi: 10.1046/j.1365-2125.1999.00896.x.
7
Best practice in therapeutic drug monitoring.治疗药物监测的最佳实践。
Br J Clin Pharmacol. 1998 Aug;46(2):95-9. doi: 10.1046/j.1365-2125.1998.00770.x.
8
Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability.预测个体患者的有效药物浓度。药效学变异性的决定因素。
Clin Pharmacokinet. 1998 Apr;34(4):323-33. doi: 10.2165/00003088-199834040-00005.
9
Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.群体药代动力学在药物研发中的作用。制药行业视角。
Clin Pharmacokinet. 1997 Apr;32(4):294-312. doi: 10.2165/00003088-199732040-00003.
10
Feasibility of effect-controlled clinical trials of drugs with pharmacodynamic hysteresis using sparse data.
Pharm Res. 1996 Dec;13(12):1804-10. doi: 10.1023/a:1016072806164.